

#### PRIOR AUTHORIZATION REQUEST FORM

#### **EOC ID:**

# **Tykerb**

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.** 

	Prescriber Name:	
Patient Name:	Supervising Physician:	
		Dhana
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact: NPI:	State Lic ID:
Group Number: Address:	Address:	State LIC ID.
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicate	No):
Filliary Filone.	Specially/facility frame (if applicat	ле). 
Drug Name and Strength:		
Directions / SIG:		
Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.		
	<u> </u>	
Q1. Please provide ICD code(s) for diagnosis		
Q2. What diagnosis is this drug being prescribed for?		
☐ Advanced or metastatic breast cancer		
☐ Other		
Q3. If you selected "other" in question 2, please provide higher recommendation per NCCN compendia or guidel		istent with a category 1 or
Q4. Is the prescribing physician an Oncologist or Hematologist	ogist?	
☐ Yes ☐ No		
Q5. Does the patient have overexpression of the HER2 rec	ceptor?	
☐ Yes ☐ No		
Q6. Will the patient be taking Tykerb in combination with capecitabine (Xeloda)?		
☐ Yes ☐ No		



#### PRIOR AUTHORIZATION REQUEST FORM

**EOC ID:** 

## **Tykerb**

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
	Supervising Physician:	
Q7. Has the patient received prior therapy with an anthracy	/cline?	
☐ Yes ☐ No		
Q8. Has the patient received prior therapy with a taxane?		
☐ Yes ☐ No		
Q9. Has the patient received prior therapy with trastuzumab (Herceptin)?		
☐ Yes ☐ No		
Q10. If the patient received prior therapy with trastuzumab	(Herceptin), did the patient have disease progression?	
☐ Yes ☐ No		
Q11. If hormone therapy is indicated, will the patient be tak	king Tykerb in combination with letrozole (Femara)?	
☐ Yes ☐ No		
Q12. Is the patient hormone receptor-positive?		
☐ Yes ☐ No		
Q13. Is the patient post-menopausal?		
☐ Yes ☐ No		
Q14. Additional Comments		
Prescriber Signature	Date	

□ Expedited/Urgent - By checking this box and signing above, I certify that applying the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function

Lack of the necessary documentation may result in a medical necessity denial. Requesting providers may speak to a SWHP pharmacist



### PRIOR AUTHORIZATION REQUEST FORM

**EOC ID:** 

**Tykerb** 

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.** 

	Prescriber Name:
Patient Name:	Supervising Physician:

or medical director at 1-800-728-7947 regarding the case to have an opportunity to help impact the decision on a request before coverage has been decided.

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document